Dopesick season 1 episode 8 Recap and FAQ
Episode Summary
In a meeting to address the opioid crisis, individuals reflect on their roles and seek amends. A doctor ponders quitting Suboxone, fearing relapse. Personal struggles with addiction and recovery are evident, as one offers help to a young woman. Purdue Pharma faces internal challenges and legal threats over missing training tapes. Emotional testimonies from victims' families highlight the human cost of the crisis. Despite a financial settlement from Purdue, public outcry demands harsher penalties. The episode concludes with reflections on the case's impact and the ongoing battle against opioid addiction.
Full Episode S01E08 Recap
Frequently Asked Questions
Who are Michael Friedman, Paul Goldenheim, and Howard Udell?
They are executives involved in the opioid crisis facing felony charges.
What is the main concern regarding the drug discussed in New Orleans?
The safety of the drug, specifically its potential for causing addiction.
Why is a doctor considering quitting Suboxone?
To regain his medical license, but he fears relapse without it.
What support does a character offer to Elizabeth Ann?
Assistance with addiction treatment, including financial help for doctor visits and therapy.
What internal issue does Purdue Pharma face?
Missing training tapes that potentially contain damaging information.
What is the community coalition's petition against OxyContin?
To recall and reformulate OxyContin to make it safer.
How does Purdue Pharma respond to the petition?
By offering a financial settlement instead of changing the drug's formulation.
What evidence turns the case against Purdue Pharma?
Training tapes showing the company trained sales reps to mislead about the drug's addictiveness.
What is the outcome of the legal battle against Purdue Pharma?
A large financial settlement and public outcry for harsher punishments.
What ongoing challenges are highlighted at the end of the episode?
The continued fight against opioid addiction and the pursuit of legal actions against pharmaceutical companies.